# Aloperine alleviates LPS-induced inflammation in bovine intestinal epithelial cells through autophagy and TLR4/p38 MAPK/NF-κB pathway

**Authors:** Panpan Tan, Yazhou Wang, Cai Zhang, Qinghua Deng, Liyin Du, Baoyu Zhao, Gulman Muhametbay, Chenxu Zhao, Jianguo Wang

PMC · DOI: 10.1186/s12917-026-05337-7 · 2026-02-20

## TL;DR

Aloperine reduces inflammation in cow intestinal cells by affecting autophagy and a key inflammation pathway, potentially helping treat calf diarrhea.

## Contribution

This study reveals Aloperine's anti-inflammatory mechanism in bovine intestinal cells via autophagy and TLR4/p38 MAPK/NF-κB pathways.

## Key findings

- Aloperine inhibits pro-inflammatory cytokines in LPS-induced bovine intestinal cells.
- Aloperine affects autophagy and the TLR4/p38 MAPK/NF-κB pathway to reduce inflammation.
- Aloperine increases intestinal barrier proteins like ZO-1 and Claudin 1.

## Abstract

Calf diarrhea is a major cause of mortality and morbidity, leading to substantial economic losses in the cattle industry. Aloperine (Alo) exhibits an anti-inflammation effect and alleviates dextran sulfate sodium salt (DSS)-induced colitis; however, it remains unclear whether Alo alleviates calf diarrhea-induced intestinal inflammation.

In this study, network pharmacology was used to discover the possible mechanism of Alo on the anti-inflammatory effect; Then, an inflammation model was induced by LPS in BIECs-21 to evaluate the protective effect of Alo on LPS-induced inflammation. Results found that a total of 68 overlapping targets of Alo and inflammation were obtained, among which ALB, AKT1, IL-6, and EGFR exhibited good affinity for Alo. In vitro experiments, Alo inhibited LPS-induced pro-inflammatory cytokine levels, increased the expression of ZO-1 and Claudin 1, and reduced the expression of proteins related to autophagy and TLR4/p38 MAPK/NF-κB pathway; the autophagy inhibitor CQ and Baf A1 results further demonstrated that Alo inhibited late stages of autophagy maturation and impaired intestinal epithelial barrier function.

These results indicated that Alo has protective effects on LPS-induced inflammation by decreasing the levels of the pro-inflammatory cytokines through the TLR4/p38 MAPK/NF-κB pathway, inhibiting late stages of autophagy maturation, and impairing intestinal epithelial barrier function.

The online version contains supplementary material available at 10.1186/s12917-026-05337-7.

## Linked entities

- **Genes:** ALB (albumin) [NCBI Gene 213], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], IL6 (interleukin 6) [NCBI Gene 3569], EGFR (epidermal growth factor receptor) [NCBI Gene 1956], TJP1 (tight junction protein 1) [NCBI Gene 7082], CLDN7 (claudin 7) [NCBI Gene 1366]
- **Chemicals:** Aloperine (PubChem CID 162147), DSS (PubChem CID 23673837), CQ (PubChem CID 2719), Baf A1 (PubChem CID 6436223)
- **Diseases:** colitis (MONDO:0005292)

## Full-text entities

- **Genes:** TLR4 (toll like receptor 4) [NCBI Gene 281536]
- **Diseases:** inflammation (MESH:D007249)
- **Chemicals:** Aloperine (MESH:C062701), LPS (MESH:D008070)
- **Species:** Bos taurus (bovine, species) [taxon 9913]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13032521/full.md

---
Source: https://tomesphere.com/paper/PMC13032521